LPL Financial LLC cut its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,159 shares of the biotechnology company’s stock after selling 80 shares during the quarter. LPL Financial LLC’s holdings in Repligen were worth $2,330,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Repligen by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,128,884 shares of the biotechnology company’s stock worth $959,665,000 after purchasing an additional 24,998 shares during the period. Invesco Ltd. grew its stake in Repligen by 3.9% during the first quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company’s stock worth $330,315,000 after purchasing an additional 65,550 shares during the period. Sands Capital Management LLC acquired a new stake in Repligen in the third quarter worth $306,666,000. WCM Investment Management LLC grew its holdings in Repligen by 5.4% in the fourth quarter. WCM Investment Management LLC now owns 1,601,982 shares of the biotechnology company’s stock worth $271,232,000 after purchasing an additional 82,356 shares during the period. Finally, State Street Corp grew its holdings in Repligen by 1.3% in the third quarter. State Street Corp now owns 1,393,580 shares of the biotechnology company’s stock worth $260,753,000 after purchasing an additional 18,369 shares during the period. Institutional investors and hedge funds own 91.00% of the company’s stock.
Repligen Stock Up 1.7 %
Repligen stock opened at $159.25 on Monday. Repligen Co. has a 52 week low of $137.65 and a 52 week high of $262.26. The stock has a market cap of $8.87 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 2.76 and a beta of 1.08. The business has a 50-day simple moving average of $163.39 and a 200 day simple moving average of $173.11.
Insider Buying and Selling
In other Repligen news, Director Martin D. Madaus bought 500 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was acquired at an average price of $156.18 per share, with a total value of $78,090.00. Following the completion of the purchase, the director now owns 1,611 shares of the company’s stock, valued at $251,605.98. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 1.10% of the stock is owned by insiders.
Wall Street Analyst Weigh In
RGEN has been the subject of a number of research reports. StockNews.com initiated coverage on shares of Repligen in a report on Thursday. They issued a “sell” rating for the company. Craig Hallum reduced their price objective on Repligen from $220.00 to $207.00 in a research note on Wednesday, May 3rd. Stifel Nicolaus reduced their price objective on Repligen from $225.00 to $210.00 in a research note on Wednesday, May 3rd. Deutsche Bank Aktiengesellschaft reduced their price objective on Repligen from $180.00 to $165.00 in a research note on Wednesday, May 3rd. Finally, TheStreet downgraded shares of Repligen from a “b-” rating to a “c+” rating in a research report on Monday, May 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.56.
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Get Rating).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.